Hypoparathyroidism versus hyperparathyroidism in pediatric dialysis patients; a single center study

2017 ◽  
Vol 6 (4) ◽  
pp. 282-289 ◽  
Author(s):  
Mitra Naseri
Keyword(s):  
Single Center ◽  
Dialysis Patients ◽  
Pediatric Dialysis ◽  
Single Center Study ◽  
Pediatric Dialysis Patients ◽  
Center Study

scholarly journals Characteristics and outcomes of hemodialysis patients with COVID-19: a retrospective single center study

PeerJ ◽  
2020 ◽  
Vol 8 ◽  
pp. e10459
Author(s):  
Yongwen Luo ◽  
Junli Li ◽  
Zhifen Liu ◽  
Heping Yu ◽  
Xiang Peng ◽  
...  
Keyword(s):  
Clinical Characteristics ◽  
Hemodialysis Patients ◽  
Control Group ◽  
Single Center ◽  
Dialysis Patients ◽  
Laboratory Findings ◽  
Single Center Study ◽  
Hospital Stays ◽  
Prolonged Hospital ◽  
Center Study

Background The coronavirus 19 (COVID-19) pandemic has heightened the threat to the health and lives of patients with comorbid diseases. Infection by COVID-19 is especially detrimental to patients on hemodialysis. In this study, we evaluated the clinical characteristics, laboratory findings, treatments and prognoses of hemodialysis patients with COVID-19. Methods A total of 16 hemodialysis patients with COVID-19 were recruited from Wuhan Fourth Hospital from 5 February to 20 March 2020 for a retrospective, single-center study. A total of 62 non-dialysis patients with COVID-19 were the control group. We collected data on the clinical characteristics, laboratory findings, treatments, and clinical outcomes of patients affected by the virus. Results Hemodialysis patients with COVID-19 had a lower incidence of fever (P = 0.001) and relatively higher incidence of pre-admission comorbidities and shortness of breath than non-dialysis patients with COVID-19 (75% vs. 61%, P = 0.467 50% vs. 33.87%, P = 0.248 ). Hemodialysis patients had lower levels of hemoglobin (P < 0.001), white blood cell counts (P = 0.015), neutrophils (P = 0.016), AST (P = 0.037), ALT (P < 0.001) and procalcitonin (P < 0.001), and higher levels of D-dimer (P < 0.001) and thrombin time (P < 0.001). Hemodialysis patients had a higher incidence of pulmonary effusion, cord-like high-density shadows, pleural thickening, and atelectasis (P < 0.05). Hemodialysis patients also had relatively higher rates of mortality and prolonged hospital stays compared with the control group. Conclusions Hemodialysis patients typically present with multiple comorbidities and are considered to be a high-risk group for COVID-19 infections. Hemodialysis patients with COVID-19 may have prolonged hospital stays and unfavorable prognoses and should be closely monitored.

scholarly journals SP521OPPORTUNISTIC PATHOGENS CARRIAGE IN PERITONEAL DIALYSIS PATIENTS: A SINGLE-CENTER STUDY

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii551-iii551
Author(s):  
Iryna Shifris ◽  
Iryna Dudar ◽  
Lurii Gonchar ◽  
Viktor Krot
Keyword(s):  
Peritoneal Dialysis ◽  
Single Center ◽  
Dialysis Patients ◽  
Single Center Study ◽  
Center Study

scholarly journals P1170ENCAPSULATING PERITONEAL SCLEROSIS: ARE CALCINEURIN INHIBITORS A RISK FOR PERITONEAL DIALYSIS PATIENTS UNDERGOING RENAL TRANSPLANTATION?

2020 ◽  
Vol 35 (Supplement_3) ◽  
Author(s):  
Valerio Vizzardi ◽  
Diana Bertoni ◽  
Vincenzo Terlizzi ◽  
Alessandra Pola ◽  
MAttia Tonoli ◽  
...  
Keyword(s):  
Mycophenolate Mofetil ◽  
Peritoneal Dialysis ◽  
Kidney Transplantation ◽  
Renal Transplantation ◽  
Calcineurin Inhibitors ◽  
Single Center ◽  
Dialysis Patients ◽  
Post Transplantation ◽  
Single Center Study ◽  
Center Study

Abstract Background and Aims Encapsulating peritoneal sclerosis (EPS) is a rare but severe complication of peritoneal dialysis (PD). Its prevalence, ranging from 0.7 to 3.3%, and its reported mortality is 25-55%. Post-transplantation encapsulating peritoneal sclerosis (PT-EPS) usually occurs within two years from PD interruption due to kidney transplantation. Calcineurin inhibitors are thought to be involved in the pathogenesis of PT-EPS. Method This is a retrospective, single-center study: all the patients who received PD for 2 or more months before kidney transplantation between 1979 and 2018 in our unit were enrolled. All PD patients diagnosed with EPS after transplantation were identified, and their data were compared with those of non-transplanted PD patients (NT-PD). Results Data from a total of 1014 PD patients were examined; 215 underwent kidney transplantation and 799 remained on PD. PT-EPS occurred in 5/215 patients (2.3%), a prevalence not significantly different from that of NT-PD (21/799= 2.6%; P = 0.39) (Table 1). Calcineurin inhibitors were administered to 178/215 (83%) patients without EPS and all 5 patients with PT-EPS (P = 0.68). Calcineurin inhibitors were associated with corticosteroids (41%), mycophenolate mofetil (34%), or both (42%). Inhibitors of mammalian targets of rapamycin were used in association with calcineurin inhibitors in 25%, with calcineurin inhibitors and steroids in 24% and steroids alone in 7%. Mortality due to PT-EPS was 4.3% vs 1.2% in NT-PD (P = 0.38) (Figure 1). Conclusion The prevalence of PT-EPS was similar to that of EPS in NT-PD. Therapy with calcineurin inhibitors did not appear to be a crucial risk key in the development of PT-EPS.

1655: Long-Term Functional Outcome in Orthotopic Bladder Replacement in Women: A Single Center Study

2007 ◽  
Vol 177 (4S) ◽  
pp. 549-549
Author(s):  
Hannes Steiner ◽  
Thomas Akkad ◽  
Christian Gozzi ◽  
Brigitte Springer-Stoehr ◽  
Georg Bartsch
Keyword(s):  
Functional Outcome ◽  
Single Center ◽  
Bladder Replacement ◽  
Single Center Study ◽  
Center Study
Sign in / Sign up

Export Citation Format

Share Document